Related Experiment Video
Updated: May 16, 2026
10:16
Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
Published on: October 8, 2015
Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas
Johanne Lade-Keller1, Kirsten M Rømer, Per Guldberg
1Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark. johanneromer@hotmail.com
The Journal of Molecular Diagnostics : JMD
|November 20, 2012
Summary
Accurate BRAF V600E mutation detection in cutaneous melanoma is crucial for Vemurafenib treatment. Five methods showed consensus above 10% tumor cells, but sensitive techniques like CADMA and TaqMan may avoid macrodissection for reliable results.
Area of Science:
- Oncology
- Molecular Diagnostics
- Genetics
Background:
- Cutaneous melanoma patients with BRAF V600E mutations respond to BRAF inhibitor Vemurafenib.
- The Cobas 4800 test is FDA-approved for patient selection, but results are sensitive to tumor cell percentage.
- Tumor cell percentage estimation in samples can vary significantly.
Purpose of the Study:
- To evaluate five different methods for detecting BRAF c.1799T>A (V600E) mutations in melanoma samples.
- To assess the impact of analytical sensitivity and tumor cell fraction on mutation detection.
- To determine the reliability of different methods, with or without macrodissection, for clinical application.
Main Methods:
- Comparison of Cobas test, Sanger sequencing, pyrosequencing, TaqMan-based PCR, and Competitive Amplification of Differentially Melting Amplicons (CADMA).
- Testing on 28 formalin-fixed paraffin-embedded (FFPE) cutaneous melanoma samples.
- Analysis of mutation detection rates based on varying tumor cell percentages.
Main Results:
- Mutation detection frequency varied based on the analytical sensitivity of each method.
- All five methods achieved 100% consensus when tumor tissue fraction exceeded 10% (or 50% of cell-dense tissue).
- Sanger sequencing, pyrosequencing, and Cobas test may require macrodissection for low tumor cell fractions, unlike CADMA and TaqMan.
Conclusions:
- Analytical sensitivity influences BRAF V600E mutation detection frequency.
- More sensitive methods like CADMA and TaqMan may offer reliable detection without macrodissection, even with low tumor cell content.
- Advanced detection methods hold promise for improved BRAF mutation testing in clinical melanoma management.
